Meeting Banner
Abstract #2484

The workflow for the validation of USPIO-enhanced MRI for the detection of lymph node metastases in rectal cancer

Rutger C.H. Stijns1, Bart W.J. Philips1, Chella van der Post2, Iris D. Nagtegaal2, Carla Wauters3, Luc J.A. Strobbe4, Fatih Polat4, Johannes H.W. de Wilt5, Stefan H.G. Rietsch6,7, Sascha Brunheim6,7, Stephan Orzada6, Harald H. Quick6,7, Jurgen F. F├╝tterer1, and Tom W.J. Scheenen1,6

1Radiology and Nuclear medicine, Radboudumc, Nijmegen, Netherlands, 2Pathology, Radboudumc, Nijmegen, Netherlands, 3Pathology, Cansius Wilhelmina hospital, Nijmegen, Netherlands, 4Surgery, Cansius Wilhelmina hospital, Nijmegen, Netherlands, 5Surgery, Radboudumc, Nijmegen, Netherlands, 6Erwin L. Hahn Institute for MR Imaging, University of Duisburg-Essen, Essen, Germany, 7High Field and Hybrid MR Imaging, University Hospital Essen, Essen, Germany

For patients with rectal cancer, the presence of lymph node metastases is an important risk factor for determining prognosis and stratifying for treatment. Clinically, lymph node staging is very challenging, especially when lymph nodes are small (<5mm). By using ultrasmall superparamagnetic iron oxide (USPIO) particles combined with (ultra) high magnetic field imaging (combidex-enhanced MRI), the detection rate of these metastatic lymph nodes may improve significantly. In this abstract we present the workflow for validating combidex-enhanced MRI by performing a node to node comparison of in vivo combidex-enhanced MRI findings with histopathological examination.

This abstract and the presentation materials are available to members only; a login is required.

Join Here